Sue‐Anne McLachlan

Generating author description...

All published works

Action	Title	Year	Authors
+ PDF Chat	Bayesian adaptive designs in a breast cancer trial with a delayed binary outcome	2024	Wei Hong Sue‐Anne McLachlan Melissa M. Moore Robert K. Mahar
+ PDF Chat	Outcome-adaptive randomisation in a multi-arm breast cancer trial	2022	Wei Hong Sue‐Anne McLachlan Melissa M. Moore Robert K. Mahar
+ PDF Chat	Improving clinical trials using Bayesian adaptive designs: a breast cancer example	2022	Wei Hong Sue‐Anne McLachlan Melissa M. Moore Robert K. Mahar

Common Coauthors

Coauthor	Papers Together
Melissa M. Moore	3
Robert K. Mahar	3
Wei Hong	3

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+ PDF Chat	Bayesian adaptive designs for multi-arm trials: an orthopaedic case study	2020	Elizabeth Ryan Sarah E Lamb Esther Williamson Simon Gates	3
+ PDF Chat	Using Bayesian adaptive designs to improve phase III trials: a respiratory care example	2019	Elizabeth Ryan Julie Bruce Andrew Metcalfe Nigel Stallard Sarah E Lamb Kert Viele Duncan Young Simon Gates	3
+ PDF Chat	When to keep it simple – adaptive designs are not always useful	2019	James Wason Peter Brocklehurst Christina Yap	3
+ PDF Chat	Improving clinical trials using Bayesian adaptive designs: a breast cancer example	2022	Wei Hong Sue‐Anne McLachlan Melissa M. Moore Robert K. Mahar	2
+	Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losses to Follow-Up, Noncompliance, and Stratification	1986	John M. Lachin Mary A. Foulkes	2
+	Not Too Big, Not Too Small: A Goldilocks Approach To Sample Size Selection	2014	Kristine Broglio Jason T. Connor Scott Berry	2
+	Monitoring event times in early phase clinical trials: some practical issues	2005	Peter F. Thall Leiko H. Wooten Nizar M. Tannir	2
+	I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy	2009	AD Barker C C Sigman Kelloff Gj NM Hylton DA Berry L. Esserman	2
+	Novel designs for multi‐arm clinical trials with survival outcomes with an application in ovarian cancer	2003	Patrick Royston Mahesh Parmar Wendi Qian	1
+	Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials	2015	P. Thall Patricia S. Fox J. Kyle Wathen	1
+ PDF Chat	Bayesian Adaptive Randomized Trial Design for Patients With Recurrent Glioblastoma	2012	Lorenzo Trippa Eudocia Q. Lee Patrick Y. Wen Tracy T. Batchelor Timothy F. Cloughesy Giovanni Parmigiani Brian M. Alexander	1
+ PDF Chat	Practical Bayesian adaptive randomisation in clinical trials	2007	Peter F. Thall J. Kyle Wathen	1
+	Predictive Probability of Success and the Assessment of Futility in Large Outcomes Trials	2006	Benjamin Trzaskoma Andreas Sashegyi	1
+ PDF Chat	A comparison of Bayesian adaptive randomization and multi‐stage designs for multi‐arm clinical trials	2014	James Wason Lorenzo Trippa	1
+ PDF Chat	Outcome-adaptive randomization for a delayed outcome with a short-term predictor: imputation-based designs	2014	Mi‐Ok Kim Chunyan Liu Feifang Hu J. Jack Lee	1
+	Tables of the number of patients required in clinical trials using the logrank test	1982	Laurence S. Freedman	1
+	Defensive efficacy interim design: Dynamic benefit/risk ratio view using probability of success	2016	Zhongwen Tang	1
+	Bayesian survival analysis in clinical trials: What methods are used in practice?	2016	Caroline Brard Gwénaël Le Teuff Marie‐Cécile Le Deley Lisa V. Hampson	1
+	Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials	2017	Jianchang Lin Veronica Bunn	1
+ PDF Chat	Comparing three regularization methods to avoid extreme allocation probability in response-adaptive randomization	2017	Yining Du John D. Cook J. Jack Lee	1
+	BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints	2017	Heng Zhou J. Jack Lee Ying Yuan	1
+	Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-Event Endpoint	2017	Guosheng Yin Nan Chen J. Jack Lee	1
+ PDF Chat	Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE	2017	Brian M. Alexander Sujuan Ba Mitchel S. Berger Donald A. Berry Webster K. Cavenee Susan M. Chang Timothy F. Cloughesy Tao Jiang Mustafa Khasraw Wenbin Li	1
+ PDF Chat	Interim Futility Monitoring Assessing Immune Therapies With a Potentially Delayed Treatment Effect	2018	Edward L. Korn Boris Freidlin	1
+	TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy	2019	Ruitao Lin Robert L. Coleman Ying Yuan	1
+ PDF Chat	Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus	2013	Jason T. Connor Jordan Elm Kristine Broglio	1
+	Bayesian Adaptive Methods for Clinical Trials	2010	Scott Berry Bradley P. Carlin J. Jack Lee Peter Müller	1
+ PDF Chat	Flexible sequential designs for multi‐arm clinical trials	2014	Dominic Magirr Nigel Stallard Thomas Jaki	1
+	Sample-Size Formula for the Proportional-Hazards Regression Model	1983	David Schoenfeld	1
+	Optimal Futility Interim Design: A Predictive Probability of Success Approach with Time-to-Event Endpoint	2014	Zhongwen Tang	1
+ PDF Chat	Response-Adaptive Randomization for Survival Trials: The Parametric Approach	2007	Lanju Zhang William F. Rosenberger	1
+ PDF Chat	Optimal two-stage designs for phase II clinical trials	1989	Richard Simon	1
+	Interim analysis: The alpha spending function approach	1994	David L. DeMets K. K. Gordon Lan	1
+	Bayesian statistical method was underused despite its advantages in the assessment of implantable medical devices	2010	Leslie Pibouleau Sylvie Chevret	1